183 related articles for article (PubMed ID: 17449802)
1. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
Hussein K; Bock O; Seegers A; Flasshove M; Henneke F; Buesche G; Kreipe HH
Blood; 2007 May; 109(9):4106-7. PubMed ID: 17449802
[No Abstract] [Full Text] [Related]
2. Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Inokuchi K; Yamaguchi H; Tamai H; Dan K
J Clin Exp Hematop; 2012; 52(2):145-7. PubMed ID: 23037633
[No Abstract] [Full Text] [Related]
3. Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.
Ringel F; Kaeda J; Schwarz M; Oberender C; Grille P; Dörken B; Marque F; Manley PW; Radimerski T; le Coutre P
Acta Haematol; 2014; 132(1):75-86. PubMed ID: 24504330
[TBL] [Abstract][Full Text] [Related]
4. [Chronic myeloid leukemia: up-to-date management].
Nakayama K; Inokuchi K
Rinsho Ketsueki; 2014 Jan; 55(1):42-55. PubMed ID: 24492036
[No Abstract] [Full Text] [Related]
5. [Clinical progress in chronic myelogenous leukemia].
Matsunaga T
Rinsho Ketsueki; 2009 Oct; 50(10):1489-99. PubMed ID: 19915358
[No Abstract] [Full Text] [Related]
6. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
7. Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.
Gambacorti-Passerini C; Piazza R
Am J Hematol; 2011 Jul; 86(7):531-2. PubMed ID: 21674581
[No Abstract] [Full Text] [Related]
8. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
Hehlmann R; Müller MC; Lauseker M; Hanfstein B; Fabarius A; Schreiber A; Proetel U; Pletsch N; Pfirrmann M; Haferlach C; Schnittger S; Einsele H; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Ehninger G; Heim D; Heimpel H; Nerl C; Krause SW; Hossfeld DK; Kolb HJ; Hasford J; Saußele S; Hochhaus A
J Clin Oncol; 2014 Feb; 32(5):415-23. PubMed ID: 24297946
[TBL] [Abstract][Full Text] [Related]
9. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
[No Abstract] [Full Text] [Related]
10. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Hughes TP; Lipton JH; Spector N; Cervantes F; Pasquini R; Clementino NC; Dorlhiac Llacer PE; Schwarer AP; Mahon FX; Rea D; Branford S; Purkayastha D; Collins L; Szczudlo T; Leber B
Blood; 2014 Jul; 124(5):729-36. PubMed ID: 24948656
[TBL] [Abstract][Full Text] [Related]
11. Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571.
Sirulink A; Silver RT; Najfeld V
Leukemia; 2001 Nov; 15(11):1795-7. PubMed ID: 11681425
[No Abstract] [Full Text] [Related]
12. [Treatment of chronic myeloid leukemia in chronic phase].
Matsumura I
Rinsho Ketsueki; 2014 Oct; 55(10):1853-9. PubMed ID: 25297749
[No Abstract] [Full Text] [Related]
13. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.
Legros L; Rousselot P; Giraudier S; Tulliez M; Huguet F; Nicolini FE; Mahon FX
Blood; 2012 Aug; 120(9):1959-60. PubMed ID: 22936742
[No Abstract] [Full Text] [Related]
14. Optimizing second-line therapy for chronic myeloid leukemia.
Raja T
Indian J Cancer; 2012; 49(1):46-56. PubMed ID: 22842168
[TBL] [Abstract][Full Text] [Related]
15. Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy.
Soderquist C; Bagg A
Blood; 2014 Oct; 124(15):2463. PubMed ID: 25436260
[No Abstract] [Full Text] [Related]
16. Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
Marin D
J Clin Oncol; 2014 Feb; 32(5):379-84. PubMed ID: 24419129
[No Abstract] [Full Text] [Related]
17. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
18. Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML.
Sorel N; Roy L; Martineau G; Guilhot F; Turhan AG; Chomel JC
Blood; 2006 Sep; 108(5):1782-3. PubMed ID: 16926302
[No Abstract] [Full Text] [Related]
19. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
[TBL] [Abstract][Full Text] [Related]
20. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]